{"id":"NCT00864851","sponsor":"Shire","briefTitle":"Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease","officialTitle":"A Multi-Center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients With Fabry Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12-29","primaryCompletion":"2012-06-01","completion":"2012-07-05","firstPosted":"2009-03-19","resultsPosted":"2014-06-06","lastUpdate":"2021-06-09"},"enrollment":44,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fabry Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Replagal","otherNames":["algasidase alfa"]}],"arms":[{"label":"Replagal 0.2 mg/kg, IV, every other week","type":"ACTIVE_COMPARATOR"},{"label":"Replagal 0.2 mg/kg, IV, weekly","type":"ACTIVE_COMPARATOR"},{"label":"Replagal 0.4 mg/kg, IV, weekly","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the safety and effectiveness of various doses of Replagal in patients with cardiomyopathy due to Fabry disease.","primaryOutcome":{"measure":"Change From Baseline to Month 12 in Left Ventricular Mass Indexed to Height (LVMI)","timeFrame":"Baseline, Month 12 (Week 53)","effectByArm":[{"arm":"Replagal 0.2 mg/kg, IV, Every Other Week","deltaMin":3.2,"sd":12.5},{"arm":"Replagal 0.2 mg/kg, IV, Weekly","deltaMin":0.5,"sd":15.8},{"arm":"Replagal 0.4 mg/kg, IV, Weekly","deltaMin":-10.3,"sd":11.8}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":12,"countries":["United States","Australia","Czechia","Finland","Paraguay","Poland","Slovenia","United Kingdom"]},"refs":{"pmids":["20730727"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":20},"commonTop":["Fatigue","Nasopharyngitis","Cough","Pain in extremity","Headache"]}}